A ALKERMES PLC
| Market Cap | $4.69B |
| P/E Ratio | 19.67 |
| Forward P/E | 13.57 |
| Dividend Yield | — |
| Beta | 0.49 |
| 52W Range | $25.17 - $36.32 |
| # Hedge Funds | 0 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Hedge Fund Ownership
| Investor 0 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|
Insider Trading
| Insider Name of the company insider who made the trade 24 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Craig C. HopkinsonEVP R&D, Chief Medical Officer | Sale | 9,000 | $35.51 | $319.60K | 01 Apr 2026 | 01 Apr 2026 |
| Gaffin David JosephEVP, CLO, Alkermes, Inc. | Sale | 2,034 | $29.76 | $60.53K | 03 Mar 2026 | 04 Mar 2026 |
| Parisi Samuel JosephVP, Finance (Interim PAO) | Sale | 6,890 | $29.29 | $201.81K | 02 Mar 2026 | 04 Mar 2026 |
| Gaffin David JosephEVP, CLO, Alkermes, Inc. | Sale | 2,034 | $29.29 | $59.58K | 02 Mar 2026 | 04 Mar 2026 |
| Nichols Christian ToddSVP, Chief Commercial Officer | Sale | 6,000 | $30.00 | $180.00K | 02 Mar 2026 | 04 Mar 2026 |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sale | 9,000 | $29.72 | $267.49K | 02 Mar 2026 | 04 Mar 2026 |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sale | 5,000 | $34.24 | $171.22K | 02 Feb 2026 | 02 Feb 2026 |
| Cooke Shane | Sale | 32,113 | $34.78 | $1.12M | 02 Feb 2026 | 02 Feb 2026 |
| Cooke Shane | Sale | 29,087 | $34.34 | $998.80K | 02 Feb 2026 | 02 Feb 2026 |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sale | 4,000 | $33.54 | $134.16K | 02 Feb 2026 | 02 Feb 2026 |
| Craig C. HopkinsonEVP R&D, Chief Medical Officer | Sale | 5,000 | $34.24 | $171.22K | 02 Feb 2026 | 02 Feb 2026 |
| Craig C. HopkinsonEVP R&D, Chief Medical Officer | Sale | 4,000 | $33.54 | $134.16K | 02 Feb 2026 | 02 Feb 2026 |
| Shane CookeDirector | Sale | 32,113 | $34.78 | $1.12M | 02 Feb 2026 | 02 Feb 2026 |
| Shane CookeDirector | Sale | 29,087 | $34.34 | $998.80K | 02 Feb 2026 | 02 Feb 2026 |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sale | 5,000 | $30.00 | $150.00K | 08 Jan 2026 | 08 Jan 2026 |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sale | 4,000 | $28.00 | $112.00K | 02 Jan 2026 | 02 Jan 2026 |
| Craig C. HopkinsonEVP R&D, Chief Medical Officer | Sale | 4,000 | $28.00 | $112.00K | 02 Jan 2026 | 02 Jan 2026 |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sale | 3,748 | $30.00 | $112.45K | 03 Dec 2025 | 05 Dec 2025 |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sale | 4,000 | $29.30 | $117.20K | 01 Dec 2025 | 01 Dec 2025 |
| Craig C. HopkinsonEVP R&D, Chief Medical Officer | Sale | 4,000 | $29.30 | $117.20K | 01 Dec 2025 | 01 Dec 2025 |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sale | 9,000 | $30.38 | $273.44K | 03 Nov 2025 | 03 Nov 2025 |
| Craig C. HopkinsonEVP R&D, Chief Medical Officer | Sale | 9,000 | $30.38 | $273.44K | 03 Nov 2025 | 03 Nov 2025 |
| Hopkinson Craig C.EVP R&D, Chief Medical Officer | Sale | 9,000 | $31.53 | $283.78K | 15 Oct 2025 | 15 Oct 2025 |
| Craig C. HopkinsonEVP R&D, Chief Medical Officer | Sale | 9,000 | $31.53 | $283.78K | 15 Oct 2025 | 15 Oct 2025 |
Frequently Asked Questions
What is ALKS stock price today?
ALKERMES PLC (ALKS) is currently trading at $28.13. The stock has a 52-week range of $25.17 to $36.32 and a market capitalization of $4.69B.
Is ALKS a good stock to buy in 2026?
ALKERMES PLC has a P/E ratio of 19.7 (forward P/E: 13.6), a dividend yield of none, and 1-year performance of -19.8%. 0 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling ALKS stock?
There have been 24 insider transactions for ALKS in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has ALKS stock performed over the past year?
ALKERMES PLC (ALKS) has returned -19.8% over the past 12 months. The stock traded between $25.17 and $36.32 during this period, and is currently at $28.13.
Which hedge funds own ALKS (ALKERMES PLC)?
0 tracked hedge funds currently hold ALKS in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is ALKS's market cap and valuation?
ALKERMES PLC (ALKS) has a market capitalization of $4.69B. The trailing P/E ratio is 19.7 and forward P/E is 13.6. The stock is classified in the Healthcare sector.
What is ALKS's revenue and profitability?
ALKERMES PLC reported revenue of $1.48B with net income of $241.66M and a profit margin of 0.16%. The stock has a beta of 0.49.
What sector is ALKS in and who are its biggest institutional holders?
ALKERMES PLC (ALKS) operates in the Healthcare sector. It is held by 0 tracked hedge funds. See the ownership table above for the complete list.